Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference newsletter

Breast Cancer

Free Subscription 12.10.2020 1 AJR Am J Roentgenol 1 Am J Clin Oncol 2 Ann Surg Oncol 4 Anticancer Res 1 BMC Cancer 2 Br J Cancer 1 Breast Cancer 1 Breast Cancer (Auckl) 1 Breast Cancer Res 5 Breast Cancer Res Treat 2 Breast J 2 Cancer Res 1 Clin Breast Cancer 1 Clin Cancer Res 1 Curr Treat Options Oncol 2 Eur J Cancer 1 Mod Pathol 1 Nat Rev Clin Oncol 1 NPJ Breast Cancer 1 Oncogene 5 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. NEWELL MS
   Editorial Comment: Breast Cancer Skip Metastases-If You Look, You Will Find Them.
   AJR Am J Roentgenol. 2020 Oct 7. doi: 10.2214/AJR.20.24836.
   PubMed        
   
   

   
   Am J Clin Oncol

2. ZOLCSAK Z, Loirat D, Fourquet A, Kirova YM, et al
   Adjuvant Trastuzumab Emtansine (T-DM1) and Concurrent Radiotherapy for Residual Invasive HER2-positive Breast Cancer: Single-center Preliminary Results.
   Am J Clin Oncol. 2020 Oct 6. doi: 10.1097/COC.0000000000000769.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

3. ISHITOBI M, Matsuda N, Tazo M, Nakayama S, et al
   Risk Factors for Ipsilateral Breast Tumor Recurrence in Triple-Negative or HER2-Positive Breast Cancer Patients Who Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy.
   Ann Surg Oncol. 2020 Oct 6. pii: 10.1245/s10434-020-09176.
   PubMed         Abstract available
   
   
4. NIZIC-KOS T, Krajc M, Blatnik A, Stegel V, et al
   Bilateral Disease Common Among Slovenian CHEK2-Positive Breast Cancer Patients.
   Ann Surg Oncol. 2020 Oct 8. pii: 10.1245/s10434-020-09178.
   PubMed         Abstract available
   
   

   
   Anticancer Res

5. YILDIRIM E, Bektas S, Gundogar O, Findik D, et al
   The Relationship of GATA3 and Ki-67 With Histopathological Prognostic Parameters, Locoregional Recurrence and Disease-free Survival in Invasive Ductal Carcinoma of the Breast.
   Anticancer Res. 2020;40:5649-5657.
   PubMed         Abstract available
   
   
6. PARK JH, Ahn JH, Kim JE, Jung KH, et al
   Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].
   Anticancer Res. 2020;40:5883-5893.
   PubMed         Abstract available
   
   
7. KIM SW, Kim HS, Na K
   Characterization of Paired Box 8 (PAX8)-expressing Metastatic Breast Carcinoma.
   Anticancer Res. 2020;40:5925-5932.
   PubMed         Abstract available
   
   
8. PERNICONE N, Peretz L, Grinshpon S, Listovsky T, et al
   MDA-MB-157 Cell Line Presents High Levels of MAD2L2 and Dysregulated Mitosis.
   Anticancer Res. 2020;40:5471-5480.
   PubMed         Abstract available
   
   

   
   BMC Cancer

9. RAINEY L, van der Waal D, Broeders MJM
   Dutch women's intended participation in a risk-based breast cancer screening and prevention programme: a survey study identifying preferences, facilitators and barriers.
   BMC Cancer. 2020;20:965.
   PubMed         Abstract available
   
   

   
   Br J Cancer

10. ZHENG G, Sundquist J, Sundquist K, Ji J, et al
    Association of post-diagnostic use of cholera vaccine with survival outcome in breast cancer patients.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01108.
    PubMed         Abstract available
    
    
11. MOROTTI M, Zois CE, El-Ansari R, Craze ML, et al
    Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer.
    Br J Cancer. 2020 Oct 8. pii: 10.1038/s41416-020-01113.
    PubMed         Abstract available
    
    

    
    Breast Cancer

12. HSU YH, Chen VC, Hsieh CC, Weng YP, et al
    Subjective and objective cognitive functioning among patients with breast cancer: effects of chemotherapy and mood symptoms.
    Breast Cancer. 2020 Oct 8. pii: 10.1007/s12282-020-01168.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Auckl)

13. DA SILVA JL, de Paula BHR, Small IA, Thuler LCS, et al
    Sociodemographic, Clinical, and Pathological Factors Influencing Outcomes in Locally Advanced Triple Negative Breast Cancer: A Brazilian Cohort.
    Breast Cancer (Auckl). 2020;14:1178223420962488.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

14. DURCKER A, Yoo BH, Khan IA, Choi D, et al
    Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity.
    Breast Cancer Res. 2020;22:105.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

15. HATONO M, Ikeda H, Suzuki Y, Kajiwara Y, et al
    Effect of isoflavones on breast cancer cell development and their impact on breast cancer treatments.
    Breast Cancer Res Treat. 2020 Oct 9. pii: 10.1007/s10549-020-05957.
    PubMed         Abstract available
    
    
16. PESCE C, Jaffe J, Kuchta K, Yao K, et al
    Patient-reported outcomes among women with unilateral breast cancer undergoing breast conservation versus single or double mastectomy.
    Breast Cancer Res Treat. 2020 Oct 8. pii: 10.1007/s10549-020-05964.
    PubMed         Abstract available
    
    
17. ABRAHAM HG, Xia Y, Mukherjee B, Merajver SD, et al
    Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database.
    Breast Cancer Res Treat. 2020 Oct 8. pii: 10.1007/s10549-020-05938.
    PubMed         Abstract available
    
    
18. FILHO OM, Giobbie-Hurder A, Lin NU, Faggen M, et al
    A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer.
    Breast Cancer Res Treat. 2020 Oct 6. pii: 10.1007/s10549-020-05928.
    PubMed         Abstract available
    
    
19. GOYAL A, Puri S, Marshall A, Valassiadou K, et al
    A multicentre prospective feasibility study of carbon dye tattooing of biopsied axillary node and surgical localisation in breast cancer patients.
    Breast Cancer Res Treat. 2020 Oct 6. pii: 10.1007/s10549-020-05961.
    PubMed         Abstract available
    
    

    
    Breast J

20. MOORMAN AM, Vink R, Rutgers EJT, Kouwenhoven EA, et al
    Incidence, clinical features, and outcomes of special types in breast cancer in a single institution population.
    Breast J. 2020 Oct 6. doi: 10.1111/tbj.14069.
    PubMed         Abstract available
    
    
21. SOSA M, Saavedra P, Alonso B, Vega V, et al
    Left-handedness is not associated with breast cancer.
    Breast J. 2020 Oct 4. doi: 10.1111/tbj.14061.
    PubMed        
    
    

    
    Cancer Res

22. SHANI O, Vorobyov T, Monteran L, Lavie D, et al
    Fibroblast-derived IL-33 facilitates breast cancer metastasis by modifying the immune microenvironment and driving type-2 immunity.
    Cancer Res. 2020 Oct 6. pii: 0008-5472.CAN-20-2116.
    PubMed         Abstract available
    
    
23. BLANCO-GOMEZ A, Hontecillas-Prieto L, Corchado-Cobos R, Garcia-Sancha N, et al
    Stromal SNAI2 is required for ERBB2 breast cancer progression.
    Cancer Res. 2020 Oct 6. pii: 0008-5472.CAN-20-0278.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

24. DE SANCTIS V, Alfo M, Vitiello C, Vullo G, et al
    Markers of Cardiotoxicity in Early Breast Cancer Patients Treated With a Hypofractionated Schedule: A Prospective Study.
    Clin Breast Cancer. 2020 Sep 10. pii: S1526-8209(20)30220.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

25. LEE HB, Lee SB, Kim M, Kwon S, et al
    Development and validation of a next-generation sequencing-based multigene assay to predict the prognosis of estrogen receptor-positive, HER2-negative breast cancer.
    Clin Cancer Res. 2020 Oct 7. pii: 1078-0432.CCR-20-2107.
    PubMed         Abstract available
    
    

    
    Curr Treat Options Oncol

26. SCOMACAO I, AlHilli Z, Schwarz G
    The Role of Oncoplastic Surgery for Breast Cancer.
    Curr Treat Options Oncol. 2020;21:94.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

27. FINK MK
    Survival in metastatic breast cancer in the ESME study and the ATRESS effect.
    Eur J Cancer. 2020 Oct 3. pii: S0959-8049(20)30495.
    PubMed        
    
    
28. DELUCHE E, Antoine A, Bachelot T, Robain M, et al
    A response letter to comments on "Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016".
    Eur J Cancer. 2020 Oct 3. pii: S0959-8049(20)30490.
    PubMed        
    
    

    
    Mod Pathol

29. AI D, Yao J, Yang F, Huo L, et al
    TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer.
    Mod Pathol. 2020 Oct 3. pii: 10.1038/s41379-020-00692.
    PubMed         Abstract available
    
    

    
    Nat Rev Clin Oncol

30. SCARANTI M, Cojocaru E, Banerjee S, Banerji U, et al
    Exploiting the folate receptor alpha in oncology.
    Nat Rev Clin Oncol. 2020;17:349-359.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

31. CHENG TD, Omilian AR, Yao S, Sanchez PV, et al
    Body fatness and mTOR pathway activation of breast cancer in the Women's Circle of Health Study.
    NPJ Breast Cancer. 2020;6:45.
    PubMed         Abstract available
    
    

    
    Oncogene

32. CHEN H, Libring S, Ruddraraju KV, Miao J, et al
    SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer.
    Oncogene. 2020 Oct 8. pii: 10.1038/s41388-020-01488.
    PubMed         Abstract available
    
    

    
    PLoS One

33. PORCIELLO G, Montagnese C, Crispo A, Grimaldi M, et al
    Mediterranean diet and quality of life in women treated for breast cancer: A baseline analysis of DEDiCa multicentre trial.
    PLoS One. 2020;15:e0239803.
    PubMed         Abstract available
    
    
34. 
    Retraction: Role of Activated Rac1/Cdc42 in Mediating Endothelial Cell Proliferation and Tumor Angiogenesis in Breast Cancer.
    PLoS One. 2020;15:e0240575.
    PubMed        
    
    
35. 
    Retraction: Inhibition of endothelial cell proliferation and tumor angiogenesis by up-regulating NDRG2 expression in breast cancer cells.
    PLoS One. 2020;15:e0240574.
    PubMed        
    
    
36. SOLIMAN SSM, Alhamidi TB, Abdin S, Almehdi AM, et al
    Effective targeting of breast cancer cells (MCF7) via novel biogenic synthesis of gold nanoparticles using cancer-derived metabolites.
    PLoS One. 2020;15:e0240156.
    PubMed         Abstract available
    
    
37. DELARMELINA E, Buzelin MA, Souza BS, Souto FM, et al
    High positivity values for bovine leukemia virus in human breast cancer cases from Minas Gerais, Brazil.
    PLoS One. 2020;15:e0239745.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: